Lattice Biologics (CVE:LBL) Stock Price Down 16.7%

Shares of Lattice Biologics Ltd (CVE:LBL) fell 16.7% during trading on Thursday . The company traded as low as C$0.03 and last traded at C$0.03. 267,000 shares changed hands during trading, a decline of 30% from the average session volume of 382,924 shares. The stock had previously closed at C$0.03.

The stock has a market capitalization of $2.80 million and a P/E ratio of -3.00. The stock’s 50 day moving average price is C$0.03.

Lattice Biologics Company Profile (CVE:LBL)

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts.

See Also: What is a capital gains distribution?

Receive News & Ratings for Lattice Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lattice Biologics and related companies with MarketBeat.com's FREE daily email newsletter.